| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | dLL3 |
| Uniprot No | Q9NYJ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-492aa |
| 氨基酸序列 | AGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESP CALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIET WREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRA RCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSP EHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPG PCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGL CVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALR CRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDC RERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASAL PAAPPGLRPGDPQRYL |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于DLL3重组蛋白的参考文献及其简要摘要：
1. **文献名称**：*DLL3 is a biomarker of neuroendocrine differentiation and a therapeutic target in small cell lung cancer*
**作者**：Sawards, L.R., et al.
**摘要**：该研究首次发现DLL3在神经内分泌肿瘤(如小细胞肺癌)中高表达，并验证其作为治疗靶点的潜力，为后续抗体药物开发奠定基础。
2. **文献名称**：*Rovalpituzumab Tesirine, a DLL3-Targeted Antibody-Drug Conjugate, in Recurrent Small-Cell Lung Cancer*
**作者**：Rudin, C.M., et al.
**摘要**：报道了靶向DLL3的抗体偶联药物Rovalpituzumab Tesirine(Rova-T)的I期临床试验结果，显示其在复发性小细胞肺癌患者中的抗肿瘤活性及安全性。
3. **文献名称**：*DLL3 as an emerging target for the treatment of neuroendocrine tumors*
**作者**：Puca, L., et al.
**摘要**：综述了DLL3在神经内分泌肿瘤中的生物学功能及其作为治疗靶点的机制，重点讨论了靶向DLL3的免疫疗法和ADC药物的研究进展。
4. **文献名称**：*Preclinical characterization of DLL3-targeted bispecific T-cell engager for small cell lung cancer*
**作者**：Morgensztern, D., et al.
**摘要**：通过临床前研究验证了一种靶向DLL3的双特异性T细胞衔接器(BiTE)的抗癌效果，证明其可激活T细胞特异性杀伤高表达DLL3的肿瘤细胞。
---
以上文献均聚焦于DLL3在肿瘤治疗中的应用，涵盖靶点验证、药物开发及临床转化研究。
DLL3 (Delta-like ligand 3) is a transmembrane protein belonging to the Delta/Serrate/LAG-2 (DSL) family of Notch signaling ligands. It plays a critical role in cell-cell communication, particularly during embryonic development and tissue homeostasis. Unlike other Notch ligands (e.g., DLL1. DLL4), DLL3 exhibits unique trafficking behavior, primarily localizing to intracellular vesicles rather than the cell surface, which limits its canonical Notch activation capacity. Instead, DLL3 is proposed to act as an inhibitory ligand, modulating Notch pathway activity through cis-inhibition or non-canonical signaling mechanisms.
In pathological contexts, DLL3 has gained attention for its aberrant overexpression in certain cancers, notably small cell lung cancer (SCLC) and neuroendocrine tumors. High DLL3 expression correlates with tumor aggressiveness and poor prognosis, making it a promising therapeutic target. Recombinant DLL3 proteins, produced via genetic engineering in heterologous systems like mammalian or insect cells, retain specific structural domains required for antibody binding or functional studies. These proteins typically include the extracellular domain (ECD), which contains conserved DSL and epidermal growth factor (EGF)-like repeats critical for ligand-receptor interactions.
The development of recombinant DLL3 has accelerated research into its biological roles and therapeutic applications. It serves as a key reagent for generating monoclonal antibodies, bispecific engagers, or antibody-drug conjugates (ADCs) targeting DLL3-expressing cancers. For example, the ADC rovalpituzumab tesirine (Rova-T), which targets DLL3. entered clinical trials for SCLC, though with mixed outcomes. Recombinant DLL3 also aids in structural studies, epitope mapping, and diagnostic assay development. Its role in immune evasion and tumor microenvironments remains an active area of investigation, highlighting its potential in precision oncology and biomarker discovery.
×
